Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
Recruiting · NCT06088381 · Registry updated 2025-11-10Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL) | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Stomatognathic Diseases, carcinoma, epithelial neoplasm, head and neck cancer, head and neck squamous cell carcinoma, neoplasm, oropharynx squamous cell carcinoma, otorhinolaryngologic disease, squamous cell carcinoma | Recruiting | Phase 2 | 2025-11-10 | NCT06088381 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| University of Maryland, Baltimore | 198 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Baltimore Washington Medical Center | Glen Burnie | United States | 7 |
| Central Maryland Radiation Oncology | Columbia | United States | 6 |
| Maryland Proton Treatment Center | Baltimore | United States | 32 |
| University of Maryland Greenebaum Cancer Center | Baltimore | United States | 20 |
| Upper Chesapeake Health | Bel Air | United States | 6 |